Moineauworld

Tag: tirzepatide

Lilly’s Retatrutide Poised to Reshape | Analysis by Brian Moineau

Posted on by Brian Moineau

TL;DR

  • Retatrutide, Eli Lilly’s triple‑agonist (GLP‑1/GIP/glucagon), produced an average 25% weight loss at week 80 at the 12 mg dose in TRIUMPH‑1 (n=2,339), with a two‑year extension approaching ~30%; knee osteoarthritis pain and obstructive sleep apnea events also improved versus placebo [1].
  • Lilly is positioning retatrutide alongside Zepbound rather than against it, using outcomes that matter to payers—obstructive sleep apnea (FDA‑approved for Zepbound in 2024) and cardiovascular risk (FDA‑approved for Wegovy in 2024)—to expand coverage beyond “weight loss only” claims [4][5].
  • Goldman Sachs models ~$95B in global anti‑obesity drug sales by 2030; even a 10% slice would be multibillion revenue, contingent on Lilly’s $3.5B Pennsylvania manufacturing build and payer adoption following outcomes labels recognized by Medicare Part D [6][8][7].

What the source said

Lilly reported that, in TRIUMPH‑1, adults with obesity but without diabetes receiving weekly retatrutide 12 mg lost a mean 25% of baseline body weight by week 80 (phase 3; n=2,339), with gastrointestinal events common and ~11% discontinuations due to adverse events [1]. Among participants with knee osteoarthritis (n≈574), pain scores declined more than on placebo; in obstructive sleep apnea (n≈243), the apnea‑hypopnea index fell by more than 30 events per hour on retatrutide versus roughly 10 per hour on placebo, suggesting clinically meaningful improvement [1]. A two‑year extension cohort neared an average ~30% loss, although no head‑to‑head trial versus semaglutide or tirzepatide was conducted in this program [1].

Why it matters

  • U.S. payers—including Medicare Part D plans, state Medicaid programs, and self‑insured employers—tend to reimburse labeled outcomes they already manage, such as cardiovascular risk and obstructive sleep apnea; Wegovy’s 2024 FDA cardiovascular‑risk label enabled Part D coverage pathways, which retatrutide could emulate if it secures outcomes‑based indications [4][7].
  • Supply will gate share just as much as efficacy; Lilly’s announced $3.5B injectable/device facility in Lebanon County, Pennsylvania adds capacity on top of prior sites to reduce shortages that limited first‑wave GLP‑1 uptake in 2023–2024 [8].

Original analysis

Efficacy stack‑up (cross‑trial optics, not equivalence)

  • Retatrutide 12 mg: −25.0% at 80 weeks in TRIUMPH‑1; two‑year extension near ~30% in a subset [1].
  • Tirzepatide 15 mg (SURMOUNT‑1): −22.5% at 72 weeks in adults with obesity [3].
  • Semaglutide 2.4 mg (STEP 1): −14.9% at 68 weeks in adults with obesity/overweight [2].

Cross‑trial comparisons are imperfect, but the ordering is consistent: retatrutide > tirzepatide > semaglutide on average percentage loss at peak doses and similar durations [1][2][3]. TRIUMPH‑1’s added endpoints—apnea‑hypopnea index reduction and knee pain improvement—map to reimbursed services like sleep studies, PAP supplies, and orthopedic visits, which strengthens the coverage case beyond pounds lost [1].

— Back‑of‑envelope: revenue sizing with shown work
Goldman Sachs pegs 2030 anti‑obesity drug sales near $95B globally [6]. If Lilly holds 45% obesity share across its franchise by 2030 and retatrutide drives 25% of Lilly’s obesity revenue, implied annual sales are $95B × 0.45 × 0.25 = $10.69B (≈$10.7B) [6]. This scenario assumes Zepbound remains the volume leader while retatrutide captures the premium‑efficacy/outcomes tier.

— 2×2: “Efficacy × Coverage” positioning

  • High efficacy / Broad coverage: Targets outcomes‑labeled indications (e.g., OSA, CV risk) that Medicare Part D and commercial plans already cover; Zepbound holds an FDA OSA label from 2024, and Wegovy holds a 2024 CV‑risk label, establishing the playbook [5][4].
  • High efficacy / Narrow coverage: Likely starting point for retatrutide at launch if weight loss dominates the label without immediate outcomes endpoints [1].
  • Moderate efficacy / Broad coverage: Semaglutide’s CV‑risk label extends access to eligible Part D beneficiaries regardless of diabetes status [4].
  • Moderate efficacy / Narrow coverage: Where earlier‑stage competitors sit until they translate weight loss into claim‑linked outcomes and codes.

— Contrarian read
Consensus says “25–30% weight loss wins by itself,” but 2024–2026 payer behavior shows labels drive budgets: Wegovy scaled Part D access with its CV‑risk indication, and Zepbound unlocked an OSA path via FDA approval in 2024 [4][5]. Retatrutide’s outcomes signals look strong, yet broad reimbursement will hinge on the exact language that lands on the U.S. label and how quickly those endpoints are reflected in coverage policies [1][7]. Expect Lilly to prioritize outcomes submissions to convert trial endpoints into billable, code‑aligned reasons to pay.

— Named‑stakeholder breakdown

  • Eli Lilly and Company: Portfolio management is key; Lilly can segment Zepbound for volume and retatrutide for peak efficacy/outcomes while de‑risking supply through the $3.5B Pennsylvania site announced in 2024 [8].
  • Novo Nordisk: Wegovy’s 2024 FDA cardiovascular indication widened Medicare Part D doors, shaping price anchors and coverage precedents that any newcomer, including retatrutide, must meet or exceed [4].
  • Medicare Part D plans: CMS signaled in 2024 that FDA‑approved CV‑risk reduction with semaglutide is coverable under Part D, setting a template for outcomes‑labeled anti‑obesity medicines and influencing employer and Medicaid policies in 2025–2027 [7][4].

What others are missing

The pivotal angle is label architecture tied to billable outcomes, not another 2–5 percentage points of weight loss; Medicare’s 2024 acceptance of Wegovy’s CV‑risk indication for Part D, plus Zepbound’s 2024 OSA approval, show that coverage flows to conditions with existing codes and utilization management playbooks (AHI thresholds, CPAP claims, CV events) [4][5]. Retatrutide’s trial endpoints mirror those realities—apnea‑hypopnea reductions and osteoarthritis pain scores—so the gating item is whether Lilly wins explicit outcomes language on the U.S. label in time to influence 2027 benefit designs and formularies [1][7].

What to watch next

  1. By December 31, 2027, Lilly submits a U.S. application for retatrutide in obesity with at least one outcomes endpoint (OSA or OA) included in the filing package.
  2. By June 30, 2028, Lilly’s Lebanon County, Pennsylvania site reaches commercial production of GLP‑1/GIP/glucagon‑class injectables to support retatrutide or Zepbound scale‑up [8].
  3. By September 30, 2028, at least two top‑10 Medicare Part D plans publish coverage criteria that explicitly reference outcomes labels (OSA or CV risk) as primary gateways for anti‑obesity drug access [7][4][5].

My take

Retatrutide has reset the efficacy ceiling to roughly 25–30% average loss over 80–104 weeks in non‑diabetic adults, which is a clinical leap but not a coverage guarantee in the United States [1]. The next competitive phase favors drugs that combine high efficacy with outcomes‑based labels that plans already know how to reimburse, plus dependable supply chains that avoid the 2023–2024 shortages. Lilly looks positioned to run that playbook: Zepbound carries an OSA label from 2024, Wegovy has a CV‑risk precedent to match, and the Pennsylvania capacity expansion supports scale. The likely 2027–2029 strategy is portfolio lock‑in: Zepbound for broad, outcomes‑anchored access and retatrutide as the premium, outcomes‑rich sequel.

Sources

  1. Eli Lilly — TRIUMPH‑1 retatrutide topline (Phase 3) and key endpoints (https://investor.lilly.com/news-releases) — Primary efficacy figures (−25% at 80 weeks), discontinuations, and OA/OSA endpoint summaries used for the trial facts.

  2. New England Journal of Medicine — STEP 1: Once‑Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2032183) — Benchmark −14.9% at 68 weeks to contextualize legacy GLP‑1 efficacy.

  3. New England Journal of Medicine — SURMOUNT‑1: Tirzepatide in Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) — Benchmark −22.5% at 72 weeks for tirzepatide to anchor cross‑trial optics.

  4. U.S. Food and Drug Administration — Wegovy cardiovascular‑risk reduction approval (2024) (https://www.fda.gov/news-events/press-announcements/) — Confirms a CV‑risk indication that Part D plans can and do cover.

  5. U.S. Food and Drug Administration — Zepbound obstructive sleep apnea approval (2024) (https://www.fda.gov/news-events/press-announcements/) — Establishes the first FDA‑approved medication for OSA in adults with obesity, a key outcomes precedent.

  6. Goldman Sachs — Anti‑obesity market outlook (~$95B by 2030) (https://www.goldmansachs.com/insights/) — Market sizing and price‑erosion context for the back‑of‑envelope revenue scenario.

  7. Centers for Medicare & Medicaid Services — Medicare Part D coverage communications for obesity drugs with outcomes labels (2024) (https://www.cms.gov/newsroom) — Clarifies how FDA‑labeled CV‑risk indications expand Part D coverage pathways.

  8. Eli Lilly — $3.5B Pennsylvania manufacturing site announcement (2024) (https://investor.lilly.com/news-releases) — Details on Lebanon County capacity build relevant to supply and launch readiness.



Related update: We recently published an article that expands on this topic: read the latest post.

Lillys Retatrutide: Next Obesity | Analysis by Brian Moineau

Posted on by Brian Moineau

A new heavyweight enters the ring: retatrutide and Lilly’s obesity play

When Eli Lilly dropped the news that retatrutide — its next‑generation obesity drug — cleared a first late‑stage diabetes trial, the headlines didn’t just hum; they roared. Retatrutide is suddenly the conversation starter across clinics, investor decks, and patient forums because it promises to be the newest pillar in Lilly’s obesity portfolio alongside the injection Zepbound and the upcoming oral candidate, orforglipron. This isn’t incremental progress; it’s a strategic bet to widen Lilly’s lead in a market that keeps redefining itself.

What just happened

Lilly announced that a late‑stage study of retatrutide met its primary and key secondary endpoints, showing meaningful benefits for patients with obesity and related cardiometabolic conditions. That readout is the first of several late‑stage trials testing retatrutide across different indications — from obesity with osteoarthritis to type 2 diabetes — and it signals that the molecule is moving from promise toward potential approval and clinical use. (finance.yahoo.com)

Transitioning from trial results to market reality will take time, but this milestone is important: it validates the concept behind retatrutide as a “triple‑agonist” engineered to target multiple metabolic pathways, and it gives Lilly data to lean on as it positions the drug against both its own products and competitors.

Why retatrutide matters now

  • Lilly already has momentum. Zepbound (tirzepatide) shifted prescribing patterns and grabbed share from older GLP‑1 therapies. Adding retatrutide to that lineup could give clinicians and patients a stronger set of options for different needs and tolerances. (cnbc.com)
  • Orforglipron, Lilly’s oral GLP‑1 candidate, aims to broaden access for people who prefer pills over injections. Together, orforglipron, Zepbound and retatrutide form a diversified portfolio that addresses both convenience and efficacy. (cnbc.com)
  • The clinical data for retatrutide have shown unusually large weight‑loss signals in earlier studies, raising expectations that it could deliver more profound reductions than current standards. If sustained and safe in broader populations, that’s a game changer for severe obesity and its comorbidities. (finance.yahoo.com)

These factors help explain why investors, clinicians and competitors are watching closely: Lilly is stacking multiple approaches — injectable, oral, and a next‑gen triple agonist — all aimed at capturing distinct slices of a massive market.

Retatrutide in context of Lilly’s strategy

Lilly is deliberate here. Rather than relying on a single blockbuster, the company is building a suite of options:

  • Zepbound: a weekly injectable (tirzepatide) that already demonstrated strong weight‑loss outcomes and broad adoption.
  • Orforglipron: an oral GLP‑1 candidate targeting the convenience segment and potentially bringing more patients into treatment.
  • Retatrutide: a next‑generation, multi‑receptor agent designed to push efficacy higher for patients who need or want more substantial results.

That three‑pronged approach hedges commercial risk and addresses different patient preferences and clinical needs. It also positions Lilly to respond to pricing pressures and payer negotiations by offering differentiated products across efficacy and route‑of‑administration. Recent policy moves and pricing agreements in the U.S. (including government negotiations and payer covers) make having alternatives strategically valuable. (time.com)

The science: why a triple approach might be better

Retatrutide is engineered to act on multiple hormonal pathways involved in appetite, satiety and metabolism. The idea is simple: combine mechanisms to produce larger, sustained weight loss than single‑pathway drugs alone. Early results have been impressive in magnitude, but the real test is durability, safety, and performance across diverse, real‑world patients.

That’s why the ongoing late‑stage program — which spans obesity with comorbid conditions, type 2 diabetes, and organ‑specific indications like chronic kidney disease — matters. If retatrutide proves safe and effective across these studies, clinicians could gain a potent tool for patients with complex metabolic disease.

The competition and what’s at stake

Novo Nordisk remains a formidable competitor with Ozempic and Wegovy in the market and its own pipeline work. But Lilly’s aggressive pipeline and the breadth of indications it’s pursuing have shifted the competitive landscape. A broadly effective retatrutide would raise the bar on weight‑loss expectations — and force payers and clinicians to rethink treatment algorithms.

At the same time, the emergence of oral GLP‑1s (including other companies’ efforts) will change access dynamics. Pills are easier to distribute and may lower barriers for many patients. Lilly’s portfolio — injectable, pill, and next‑gen triple agonist — is designed to capture patients at multiple points along that adoption curve. (cnbc.com)

What to watch next

  • Upcoming readouts from the other TRIUMPH trials and indications, especially those focused on diabetes and organ‑specific outcomes.
  • Safety and tolerability data across larger and more diverse populations.
  • How payers respond: pricing, coverage decisions, and whether combinations of these drugs alter formularies.
  • Real‑world adoption patterns once orforglipron and (if approved) retatrutide become available.

Key points to remember

  • Retatrutide just cleared a meaningful late‑stage milestone, marking a significant step toward broader clinical use. (finance.yahoo.com)
  • Lilly is combining three product types — injection, pill, and a next‑gen triple agonist — to cover convenience and efficacy needs. (cnbc.com)
  • The stakes are high: safety, durability, access and payer decisions will determine whether retatrutide reshapes care or becomes another option among many.

My take

This is a pivotal moment for metabolic medicine. Retatrutide’s initial late‑stage win is the kind of data that shifts expectations, but the broader impact will depend on replicated results, safety, and how the market digests another powerful tool. Lilly’s multi‑product strategy is smart: it reduces single‑product risk and gives physicians flexibility. Still, success will require more than impressive trial numbers — it will require thoughtful rollout, accessible pricing, and clear guidance on where retatrutide fits in a crowded and evolving treatment landscape.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.

Lilly Surges as Novo Nordisk Falters | Analysis by Brian Moineau

Posted on by Brian Moineau

When two giants diverge: why Eli Lilly raced ahead while Novo Nordisk stumbled

It felt like a tilt-shift moment on the pharma leaderboard: one title-holder sprinting forward and another who’d dominated the same lane suddenly slowing to a stumble. On Wednesday, Eli Lilly’s share price surged after a bullish earnings call and an outsized 2026 revenue outlook, while Novo Nordisk’s stock slid on a gloomy forecast and mounting competitive pressures. The result is a widening gap between the two companies that had been racing in lockstep for the GLP‑1 weight-loss boom. (finance.yahoo.com)

Quick hits: what moved the market

  • Eli Lilly raised expectations for 2026 revenue — targeting roughly $80–$83 billion — and beat Q4 estimates, giving investors confidence in continued growth. (finance.yahoo.com)
  • Novo Nordisk surprised the market with guidance that implied a 5%–13% sales decline for 2026, signaling pressure from competition, pricing changes and regulatory headwinds. (finance.yahoo.com)
  • Broader disruptions — cheaper compounded products, new entrants, and political scrutiny over drug pricing — accelerated the split between the two stocks. (investopedia.com)

How we got here: background and recent events

  • The context is the GLP‑1 revolution. Drugs like Lilly’s tirzepatide (Zepbound/Mounjaro family) and Novo’s semaglutide (Wegovy/Ozempic) redefined treatment for obesity and type 2 diabetes and produced rapid revenue growth for both companies in recent years. That boom set up intense competition and sky‑high expectations. (financialcontent.com)

  • Eli Lilly’s recent performance combined strong quarterly revenue (Q4 revenue above estimates) with a bold 2026 outlook — and investors interpreted that as evidence Lilly’s manufacturing, distribution and product mix are scaling well. The company’s oral GLP‑1 candidate and expanding market share in obesity care add to the narrative. (finance.yahoo.com)

  • Novo Nordisk’s outlook, by contrast, acknowledged a “painful transition” in a market facing price pressure and growing competition. Management signaled slower growth and even a potential sales decline next year — a message that markets punished quickly. Compounding this, cheaper and sometimes legally contested alternatives (and talk of regulatory intervention) have created noise and uncertainty around pricing and volume. (finance.yahoo.com)

Why the stocks diverged — the investor read

  • Forecasts matter: investors rewarded Lilly for projecting aggressive top‑line growth and beating quarterly expectations; they punished Novo for guiding to weaker sales. Forecast direction can change how a company is priced more than current-year results. (finance.yahoo.com)

  • Product positioning and pipeline: Lilly’s expanding GLP‑1 franchise (including oral programs) and its ability to ramp supply were read as durable advantages. Novo still leads in semaglutide brand recognition, but its comments suggest pricing and uptake will be tougher in 2026. (investing.com)

  • Pricing and politics: the U.S. spotlight on drug costs and moves by payers and regulators to curb prices change the math for high‑price specialty drugs. Lower list prices or tougher reimbursement reduce revenue even if patient demand remains large. That dynamic hit Novo’s outlook hard. (financialcontent.com)

  • Competitive noise: cheaper compounded formulations and new entrants (or an oral competitor) compress margins and create headline risk; investors reacted to both actual guidance and the possibility of faster price erosion. (investopedia.com)

What this means for investors and the market

  • Valuation repricing may be real. Stocks that once moved together now reflect differentiated risk profiles: Lilly seen as growth‑accelerating, Novo viewed as facing short‑term revenue headwinds. That opens trading and allocation decisions for investors who prefer growth vs stability. (marketbeat.com)

  • Short‑term volatility will likely persist. Headlines about pricing policies, regulatory rulings on compounded products, trial readouts for oral GLP‑1s, and quarterly guidance will swing sentiment quickly. (investopedia.com)

  • Longer-term winners will be decided by execution, not narrative. Lower prices could expand access and volume, which benefits whichever company controls manufacturing, distribution and payer relationships most effectively. Conversely, sharp margin erosion without offsetting volume gains would hurt profits. (financialcontent.com)

Risks and unanswered questions

  • Will government and payer pressure force materially lower U.S. prices, and if so, can either company offset that with volume gains? (financialcontent.com)
  • Which oral GLP‑1 or alternative delivery platforms will gain market share, and how will side‑effect profiles and adherence affect real‑world outcomes? (investing.com)
  • Can either company defend pricing through patented delivery technologies, programmatic partnerships or by driving superior clinical outcomes? (investing.com)

My take

The split between Eli Lilly and Novo Nordisk isn’t a moral victory for one and a knockout for the other — it’s a re‑rating. Markets are reacting to forward guidance, pipeline signals and a changing regulatory environment. Lilly’s optimistic 2026 outlook and operational momentum bought it a premium; Novo’s candid warning about tougher times cost it investor confidence. Over the long run, scale, patient access and pricing mechanics will determine which company translates the GLP‑1 opportunity into sustainable profits. For now, expect headline‑driven moves and a lot of noise as the industry reshuffles.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.